Design and synthesis of new 2-aryl, 3-benzyl- (1,3-oxazolidine or 1,3-thiazolidine)-4-ones as selective cyclooxygenase (COX-2) inhibitors

Medicinal Chemistry Research

Volumn 19, Issue 8, 2010, Pages 782-793

  Zarghi, A ^a   Arefi, H ^a   Dadrass, O G ^b   Torabi, S ^c  

^a SHAHID BEHESHTI UNIVERSITY   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

1,3 oxazolidines; 1,3 thiazolidines; COX 2 inhibitors

Indexed keywords

3 BENZYL (1,3 OXAZOLIDINE) 4 ONE DERIVATIVE; 3 BENZYL (1,3 THIAZOLIDINE) 4 ONE DERIVATIVE; 3 BENZYL 2 (4 METHYLSULFONYLPHENYL) 1,3 OXAZOLIDINE 4(5H) ONE; 3 BENZYL 2 (4 METHYLSULFONYLPHENYL) 1,3 THIAZOLIDINE 4(5H) ONE; 3 BENZYL 2 (4 METHYLSULFONYLPHENYL) 5 METHYL(1,3 OXAZOLIDINE) 4(5H) ONE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONFORMATIONAL TRANSITION; DRUG BINDING SITE; DRUG DESIGN; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SPECIFICITY; IC 50; IN VITRO STUDY; MOLECULAR MODEL; NONHUMAN; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

EID: 78650753358     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00044-009-9230-8     Document Type: Article

References (18)

1. Abouzid KW, Bekhit SA (2008) Novel anti-inflammatory agents based on pyridazinone scaffold; design, synthesis and in vivo activity. Bioorg Med Chem 16:5547-5556
2. Dogné JM, Supuran CT, Pratico D (2005) Cardiovascular effects of the coxibs. J Med Chem 48:2251-2257
3. Fu JY, Masferrer JL, Seibert K, Raz A, Needleman P (1990) The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265:16737-16736
4. Herschman HR (1996) Prostaglandin synthase 2. Biochem Biophys Acta 1299:125-140
5. Katori M, Majima M (2000) Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors. Inflamm Res 49:367-392
6. Kawamori T, Rao CV, Seibert K, Reddy BS (1998) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58:406-412
7. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, Isakson PC, Stallings WC (1996) Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384:644-648
8. Penning TD, Tally JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers R, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC (1997) Synthesis and biological evaluation of the 1, 5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC-b58635, celecoxib). J Med Chem 40:1347-1365
9. Prasit P, Wang Z, Brideau C, Chan CC, Charlson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay J, Gresser M, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini JO, Neil GP, Quellet M, Percival MD, Perrier H, Riendeau D, Rodger I, Tagari P, Therien M, Vikers P, Wong E, Xu L, Young RN, Zamboni R, Boyce S, Rupniak N, Forrest M, Visco D, Patrick D (1999) The discovery of rofecoxib, [MK 966, Vioxx, 4-(40-methylsulfonylphenyl)-3- phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg Med Chem Lett 9:1773-1778
10. Rammana Reddy MV, Billa VK, Pallela VR, Mallireddigari RB, Boominathan R, Gabriel JL, Reddy EP (2008) Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3-trifluoromethyl-5- indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors. Bioorg Med Chem 16:3907-3916
11. Riendeau D, Percival MD, Brideau C, Dube CS, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greig G, Guay J, Girard Y, Prasit P, Zamboni R, Rodger IW, Gresser M, Ford-Hutchinson A, Young RN, Chan CC (2002) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296:558-566
12. Scholz M, Ulbrich HK, Dannhardt G (2008) Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4, 5-Diaryl isoselenazoles. Eur J Med Chem 43:1152-1159
13. Smith WL, DeWitt DL (1996) Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol 62:167-215
14. Solomon DH (2005) Selective cyclooxygenase 2 inhibitors and. cardiovascular events. Arthritis Rheum 52:1968-1978
15. Vane JR, Botting RM (1998) Anti-inflammatory drugs and their mechanism of action. Inflamm Res 47:S78-S87
16. Zarghi A, Rao PNP, Knaus EE (2007a) Synthesis and biological evaluation of methanesulfonamide analogues of rofecoxib: replacement of methanesulfonyl by methanesulfonamide decreases cyclooxygenase-2 selectivity. Bioorg Med Chem 15:1056-1061
17. Zarghi A, Rao PN, Knaus EE (2007b) Design and synthesis of new rofecoxib analogs as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of the methanesulfonyl pharmacophore by a N-acetylsulfonamido bioisostere. J Pharm Pharmaceut Sci 10:159-167
18. Zarghi A, Najafnia L, Daraie B, Dadrass OG, Hedayati M (2007c) Synthesis of 2, 3-diaryl-1, 3-thiazolidine-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors. Bioorg Med Chem Lett 17:5634-5637